KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer

    The oncologist, 2020.

    Cited by: 0|Bibtex|Views8|Links
    WOS

    Abstract:

    Pembrolizumab had manageable toxicity, linear serum exposure, and encouraging antitumor activity in Chinese patients with advanced NSCLC.

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments